Abstract
1 Drug effects on dopamine catabolism of the mesolimbic dopaminergic pathway have been investigated using a sensitive radioenzymatic assay for 3,4-dihydroxyphenylacetic acid (DOPAC). 2 Turnover of DOPAC was less rapid in the ventral tegmentum (containing somata and dendrites) than in the nucleus accumbens (containing nerve terminals): 9 and 115 ng g-1 min-1 for ventral tegmentum and nucleus accumbens respectively. 3 Reserpine (5 mg/kg, 1 h) elevated DOPAC concentration to a greater extent in ventral tegmentum than in nucleus accumbens. 4 Neuroleptic drugs elevated DOPAC levels in ventral tegmentum and nucleus accumbens. Thioridazine, sulpiride and clozapine, thought to act preferentially on the mesolimbic system, caused a similar elevation in both brain regions. 5 gamma-Butyrolactone (750 mg/kg) caused a significant decrease in the DOPAC concentration in ventral tegmentum after 0.5 and 1 h, while DOPAC levels in nucleus accumbens were not significantly altered at these time intervals. 6 Similarities exist between the dopamine catabolism in somatodendritic and nerve terminal regions of mesolimbic dopaminergic neurones in the response to neuroleptic drugs, but differences in catabolism are evident following certain pharmacologica...Continue Reading
References
Jun 13, 1975·Science·L L Iversen
May 1, 1976·The Journal of Pharmacy and Pharmacology·G Bartholini
Oct 1, 1976·Experimental Neurology·E G McGeerP L McGeer
Jan 1, 1976·International Review of Neurobiology·F C ColpaertJ E Leysen
Mar 1, 1976·European Journal of Pharmacology·R H RothJ R Walters
Nov 24, 1977·Experimental Brain Research·C J WilsonE Fifková
Aug 15, 1977·European Journal of Pharmacology·F KaroumR J Wyatt
Sep 1, 1977·Journal of Neurochemistry·A ArgiolasG L Gessa
Jan 1, 1977·Neuroscience·D A Carter, H C Fibiger
Jun 1, 1976·European Journal of Pharmacology·B H Westerink, J Korf
Sep 23, 1976·Nature·F HeftiW Lichtensteiger
Oct 21, 1976·Nature·P H Kelly, K E Moore
Nov 1, 1976·European Journal of Pharmacology·B H Westerink, J Korf
Oct 15, 1976·Life Sciences·M Da Prada, Zürcher
Jan 1, 1975·Psychopharmacologia·A J PijnenburgJ M Van Rossum
Jan 17, 1975·Brain Research·A Björklund, O Lindvall
Feb 1, 1975·Biochemical Medicine·B H Westerink, J Korf
Mar 18, 1976·Nature·J KorfB H Westerink
Mar 18, 1976·Nature·L B GeffenL L Iversen
Aug 1, 1973·Archives of General Psychiatry·J R Stevens
Aug 1, 1972·Biochemical Pharmacology·J R Walters, R H Roth
Feb 1, 1974·Journal of Neurochemistry·A S HornR J Miller
Jul 1, 1971·British Journal of Pharmacology·S Roffler-TarlovP Tegerdine
May 1, 1969·British Journal of Pharmacology·G F MurphyD F Sharman
Aug 1, 1966·Journal of Neurochemistry·J Glowinski, L L Iversen
Citations
Jan 1, 1985·Psychopharmacology·F M Scalzo, L P Spear
Jan 1, 1981·Psychopharmacology·A L Gundlach, P M Beart
Nov 21, 1983·Brain Research·Y TakanoH O Kamiya
Nov 26, 1990·Brain Research·G E JaskiwD R Weinberger
May 6, 1996·European Journal of Pharmacology·D M GilliesD M Jackson
May 22, 1989·Neuroscience Letters·P W KalivasL Abbott
Jan 1, 1989·Neuroscience·D T ManallackP M Beart
Sep 1, 1989·Journal of Neurochemistry·P M BeartD T Manallack
Aug 1, 1985·Journal of Neurochemistry·M J ChristieP M Beart
Feb 1, 1982·Journal of Neurochemistry·A L Gundlach, P M Beart
Sep 1, 1982·Journal of Neurochemistry·A L GundlachP M Beart
Nov 1, 1982·Journal of Neurochemistry·P M Beart, D McDonald
Sep 1, 1982·The Journal of Pharmacy and Pharmacology·P M Beart, D McDonald
Jan 1, 1981·The Journal of Pharmacy and Pharmacology·A L Gundlach, P M Beart
May 23, 2000·Journal of Neurochemistry·N N Chen, W H Pan